Tobacco Regulation and Products

Share

In 2009, we won a hard-fought campaign that led to Congress passing a law granting the U.S. Food and Drug Administration (FDA) the authority to regulate all tobacco products, including cigarettes, e-cigarettes, cigars and hookah. Yet, it took the FDA seven years to begin their oversight of many of these products with much more work left to be done. 

Recent spikes in the use of e-cigarettes makes clear that more must be done to regulate tobacco products and the industry's deceptive marketing practices.  We are working to ensure the government fully leverages the regulatory power it now possesses to protect children and adults. 

Tobacco use costs our nation nearly $300 billion in health care and productivity losses each year.

Take Action

Protect our Children from Big Tobacco

The tobacco industry has preyed upon young people by marketing products that appeal to kids.

Latest Updates

August 20, 2026
Oregon

OREGON CITY, ORE. – The American Cancer Society Cancer Action Network (ACS CAN) applauds Oregon City Mayor Denyse McGriff for calling on fellow mayors and city councils across Clackamas County to join her in asking for the Board of County Commissioners to end the sale of menthol cigarettes and all

July 14, 2026
National

A coalition of public health organizations, pediatricians and parents today filed a federal lawsuit challenging the Food and Drug Administration’s new enforcement policy that allows e-cigarette and nicotine pouch products to be marketed and sold without the scientific review and marketing authorization required by federal law.

June 30, 2026
National

WASHINGTON, D.C. – The following is a statement from Lisa Lacasse, president of the American Cancer Society Cancer Action Network: “The FDA’s job is to protect public health, not expand the profit margins of Big Tobacco. Authorizing new modified risk claims for 20 Zyn nicotine products – including flavored

June 1, 2026
Arizona

Public health organizations across Arizona are raising concerns that HB 4001, which recently passed the Arizona Senate, leaves significant gaps in protecting kids from tobacco and nicotine products like e-cigarettes and nicotine pouches. The American Cancer Society Cancer Action Network (ACS CAN) along with the American Heart Association, American Lung

Tobacco Regulation and Products Resources

The Family Smoking Prevention and Tobacco Control Act (TCA) requires manufacturers of all new tobacco products to submit an application to the Food and Drug Administration’s Center for Tobacco Products (CTP) for premarket review to prove that the sale of their product is “appropriate for the protection of public health” prior to going on to the market. This is one of the most important provisions of the TCA, and was intended to prevent new, harmful tobacco products from ever being sold. Unfortunately, the premarket review of all new tobacco products has never taken full effect due to lack of enforcement by the agency, the tobacco industry continuing to sell new products without CTP authorization and implementation disruptions.

The Family Smoking Prevention and Tobacco Control Act (TCA) prohibits tobacco manufacturers from using misleading descriptors about their products and requires a substantive scientific review by the Food and Drug Administration's Center for Tobacco Products prior to using any "modified risk" claim. This is one of the most important provisions of the TCA as it directly addresses the tobacco industry's deceptive marketing practices about the harm of its products.

In March 2026, FDA released the “Flavored Electronic Nicotine Delivery Systems (ENDS) Premarket Applications – Considerations Related to Youth Risk; Draft Guidance for Industry." Draft Guidance provides FDA's current thinking about the topic of the guidance. The undersigned public health, medical, civil righs and community organizations conclude that the Draft Guidance fails to recognize the well-established history of signficant variations in youth flavor preferences over time, often caused by regulatory decisions, and this fundamental flaw threatens to open the regulatory door to a wide array of FDA-authorized products that would appeal and be accessible to youth, without signficant countervailing health benefits to adults who smoke.